- CEO
- Chun Pan
- Full Time Employees
- 518
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- No. 1228 Chang Jiang Bei Road Changzhou JS China 213034
- IPO Date
- Jun 28, 2002
- Business
- Changmao Biochemical Engineering Company Limited (0954.HK) manufactures and markets four-carbon organic acids and derivatives principally for food additives, pharmaceuticals, chemicals, biomedicine, new materials and agriculture applications; core products include L-malic acid, DL-malic acid, L(+)-tartaric acid, D-tartaric acid, DL-tartaric acid, fumaric acid, maleic acid, aspartic acid, aspartame, cream of tartar, sodium pantothenate, pyrroloquinoline quinone (PQQ), L(+)-diethyl L-tartrate, diethyl L-malate, dimethyl L-malate and 1,2,3,4-butanetetracarboxylic dianhydride. Founded in 1992 and headquartered in Changzhou, Jiangsu Province, China, the company operates production facilities through subsidiaries including Shanghai Changmao Biochemical Engineering Company Limited, Changmao Biochemical Lianyungang Company Limited and Changmao (Dalian) New Materials Company Limited, with sales networks spanning Mainland China, Europe, Asia Pacific, the United States and other regions; it maintains research centers such as the Chirotechnology Centre in Changzhou and Shanghai Medical Life Science Research Centre Limited ("Shanghaimed"). The company listed on the Hong Kong GEM board in 2002 before transferring to the Main Board in 2013, achieved milestones including the first butane-maleic anhydride production line in Jiangsu Province in 2017 and establishment of the Dalian facility in 2020, and in 2024 launched 14 new R&D projects, secured one new invention patent, filed three additional patent applications, completed registration of one new pharmaceutical excipient alongside multiple raw material and excipient registrations, and advanced key import substitution initiatives while supporting Dalian plant scale-up for chemical production, nutraceuticals, APIs, feed additives and electronic-grade chemicals amid reported revenue of CNY543 million and net losses.